Nutriband Inc
NTRB
Company Profile
Business description
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Contact
121 South Orange Avenue
Suite 1500
OrlandoFL32801
USAT: +1 407 377-6695
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 January 2026
Employees
3
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,094.90 | 27.60 | -0.30% |
| CAC 40 | 7,797.20 | 21.02 | -0.27% |
| DAX 40 | 23,301.42 | 27.82 | -0.12% |
| Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
| FTSE 100 | 9,217.61 | 21.95 | 0.24% |
| HKSE | 26,908.39 | 469.88 | 1.78% |
| NASDAQ | 22,333.96 | 14.79 | -0.07% |
| Nikkei 225 | 44,790.38 | 111.89 | -0.25% |
| NZX 50 Index | 13,228.38 | 6.51 | -0.05% |
| S&P 500 | 6,606.76 | 8.52 | -0.13% |
| S&P/ASX 200 | 8,818.50 | 30.00 | -0.34% |
| SSE Composite Index | 3,876.34 | 14.48 | 0.37% |